The Shanghai Composite Index experienced narrow-range fluctuations on April 15, closing the morning session up 0.37% at 4041.45 points. The Shenzhen Component Index fell 0.25%, while the ChiNext Index declined 0.23%. The Beijing Stock Exchange 50 Index gained 0.81%, and the STAR 50 Index rose 1.4%. The CSI A500 Index increased 0.14%, with A-share turnover reaching 1.59 trillion yuan during the morning session.
In money market operations, the central bank conducted a 5 billion yuan 7-day reverse repo at a fixed rate of 1.4%, fully meeting primary dealers' demand. Wind data shows that 5 billion yuan in reverse repos matured on the same day, resulting in a complete offset of maturing funds.
On the policy front, the National Energy Administration convened a meeting to advance regional hydrogen energy pilot programs, reviewing progress and outlining next-phase priorities. The meeting emphasized anchoring goals for the 16th Five-Year Plan period, strengthening technological innovation and demonstration of first-of-a-kind equipment, advancing institutional innovations in hydrogen trading and green certification, enhancing policy support and resource allocation, improving inter-pilot coordination, and accelerating the development of hydrogen as a future industry.
In technological developments, the HH-200 commercial unmanned aerial transport system, independently developed by the Aviation Industry Corporation of China, successfully completed its maiden flight at the Weinan operational base of the civil aircraft test flight center, marking progress in China's large commercial unmanned transport equipment sector.
Sector-wise, CPO concept stocks showed repeated activity, with companies like Huashengchang, Cambridge Technology, and Yuanjie Technology leading gains. Innovative drug概念 stocks also performed strongly, with Harbin Pharmaceutical Group Co.,Ltd. hitting two consecutive daily limits. Other notable gainers included Borui Pharmaceutical, Realcan Pharmaceutical, Jinling Pharmaceutical, Hisun Pharmaceutical, and Luyan Pharma.
Recently, the National Medical Products Administration issued implementation opinions on "AI + drug regulation," aiming to establish a smart, agile, and ecologically coordinated drug safety governance framework by 2035. The guidelines are expected to promote innovative AI applications across the entire lifecycle of drugs, medical devices, and cosmetics, enhancing public medication safety and industrial development.
Based on integrated analysis of broker research reports, here are brief profiles of four companies for reference:
1. Borui Pharmaceutical Multiple formulations of BGM0504 and BGM1812 are expected to enter clinical stages this year, with overseas population data enhancing global competitiveness. — Dongwu Securities
2. Youcare Pharmaceutical Group Co.,Ltd. Several new drugs are nearing market launch, with small nucleic acid drugs showing potential for overseas licensing. — Huaxin Securities
3. Zhejiang Conba Pharmaceutical Co.,Ltd. The company will pursue high-quality acquisitions under its traditional Chinese medicine health strategy, integrating industry resources to expand business boundaries. It aims to leverage policy opportunities for breakthrough market access and strengthen core competitiveness to support long-term sustainable development. — Huachuang Securities
4. Shandong Buchang Pharmaceuticals Co.,Ltd. The marginal impact of medical insurance policies on performance has weakened, goodwill impairment risks have been mitigated, and future earnings are expected to stabilize. — Guohai Securities
Comments